Q1 FY27 Quarterly Activities Report & Appendix 4C
Filed with ASX · · 11 pages · English
Summary by 6ix AI
Additionally, the company has implemented a cost base reset, reducing annualized cash operating costs significantly compared to the previous fiscal year. The report also discusses the company's cash flow situation, including a net operating cash outflow and plans for further funding through a placement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Microba Life Sciences Limited on 6ix
Earlier from Microba Life Sciences
- Microba secures $2m placement and increases cost reductions
- Date of AGM and closing date for Director Nominations
- Notification of cessation of securities - MAP
- Microba launches GI Navigator in Australia and the UK
- Change in substantial holding
Later from Microba Life Sciences
- Proposed issue of securities - MAP
- Update on Commercial Terms for Proposed Merger with MAP
- Final Director's Interest Notice - Gene Tyson
- Final Director's Interest Notice - Ian Frazer
- Letter to Shareholders, Notice of AGM & Proxy Form
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences